派林生物：全资子公司获得药物临床试验批准

Core Viewpoint - Palin Bio (000403) announced on December 23 that its wholly-owned subsidiary, Guangdong Shuanglin, received approval from the National Medical Products Administration for a clinical trial of intravenous human immunoglobulin (pH4) after changes in the production process [1] Group 1 - The approval allows Guangdong Shuanglin to conduct clinical trials for the modified production process of intravenous human immunoglobulin [1]